Suggested remit: To appraise the clinical and cost effectiveness of histamine dihydrochloride with interleukin-2 within its marketing authorisation for maintenance treatment of acute myeloid leukaemia.
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 1627

Email enquiries


Key events during the development of the guidance:

Date Update
26 June 2020 Suspended: The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets histamine dihydrochloride have ceased to engage with NICE regarding this appraisal. NICE have therefore taken the decision to suspend this topic from the work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please contact the project manager for this appraisal Emily Richards on (44 (0)161 413 4070 or via email on
26 June 2020 Suspended. _

For further information on our processes and methods, please see our CHTE processes and methods manual